NEJM: Enmeluamine used to treat desomnivoic prostate cancer

Preliminary test results showed that for patients with non-metastatic, de-resistant prostate cancer treated with androgen deprivation, enmelulamine significantly improved the non-metastatic survival rate and rapidly raised the level of prostate-specific antigen (PSA)Recently, researchers published the effect of enmelua mine on the overall survival rate of patientsin this randomized double-blind Phase III trial, men with non-metastatic, decalcited prostate cancer were randomly treated with 160 mg of enpratolamine or placebo once a day on the basis of androgen deprivation therapyThe main endpoint of the study was the total survival rateas of October 15, 2019, 933 patients in the Enmeluamine group had 288 deaths (31%) and 178 (38%) of the 468 patients in the placebo groupThe total survival of the placein in the enmelua mine group was 67.0 months and the placebo group was 56.3 months (death risk ratio: 0.73)The adverse event rate of the Enmelu amine group at level 3 or above was 17/100 years in patients, and in the placebo group for 20/100 patient years, the most common adverse events were fatigue and musculoskeletal eventsstudies suggest that the combination of enmelua androgen deprivation therapy can prolong the total survival of patients with non-metastatic, de-resistant prostate cancer